Home
Storia in 1 fonti
AstraZeneca looks to AI to ease risk in late-stage trials, speed up filings
AstraZeneca CEO Pascal Soriot says AI could boost late-stage trial success and speed FDA filings, following Wainua's surprise Phase 3 failure.
Raccontata da
endpoints.news
Timeline cronologica
- ·
AstraZeneca’s pipeline struggles continue as it reports disappointing data in cancer, rare disease
AstraZeneca posts Q2 pipeline setbacks: mixed ADC data in gastric cancer, an Ultomiris TMA trial miss and an Imfinzi liver cancer failure.
- ·
AstraZeneca looks to AI to ease risk in late-stage trials, speed up filings
AstraZeneca CEO Pascal Soriot says AI could boost late-stage trial success and speed FDA filings, following Wainua's surprise Phase 3 failure.